@entity5305 associated XXXX : a clinical audit to study prevalence, drug history and effects of drug withdrawal.

@entity1 @entity227 @entity137 @entity5305 @entity302 @entity4542
PURPOSE: To survey clinical visual function including quantitative manual perimetry results in a group of @entity1 taking @entity5305 ; to assess the severity of any field defects; to tabulate cumulative and daily doses of medication and to assess possible changes in visual function over time. METHOD: A prevalence study of 100 out of 183 @entity1 currently attending a tertiary referral @entity302 centre who were taking or had recently discontinued @entity5305 (duration 83-3570 days; mean 1885 days) as part of combination anticonvulsant therapy. Complete neuro-ophthalmic examination including Goldmann kinetic perimetry was performed and monocular @entity4542 ( @entity4542 ) to the I/4e isopter calculated. @entity1 were followed up at 6-monthly intervals for not less than 18 months. RESULTS: Acuity and colour vision remained stable in all @entity1 regardless of changes in visual fields. Twenty per cent of @entity1 had significant constriction of their visual field defined as a monocular @entity4542 of 30 degrees or less. Males were significantly more likely to be severely affected than females (P < 0.01). Twenty one @entity1 were followed after discontinuing @entity5305 treatment. Only three of these showed a change in @entity4542 of 10 degrees or more with two deteriorating and one improving. No correlation between treatment duration or cumulative dosage/kg and the severity of defects could be demonstrated. CONCLUSIONS: Earlier reports of a high prevalence of both moderate and more serious field defects were confirmed in @entity1 taking @entity5305 but not in @entity302 @entity1 taking other anti-convulsants. We found no evidence of progression or resolution of @entity227 on discontinuing the drug, and no relationship between dose history and @entity227 . An @entity137 retina may underlie the pathogenesis of the @entity227 in some @entity1 .
